0-T unit. Two independent readers reviewed images PRIMA-1MET research buy acquired with conventional and dual-source

parallel RF transmission for detection of focal liver lesions, with separate reading of a third radiologist, including all available imaging findings, clinical history, and histopathologic findings, as reference. Image quality and lesion conspicuity were rated on five-and three-point evaluation scales, respectively. Contrast ratios between focal liver lesions and adjacent liver parenchyma were calculated. Significance was determined by using nonparametric Wilcoxon signed-rank and marginal homogeneity tests.

Results: With the reference standard, 106 index lesions were identified in 22 patients. Detection rate significantly improved from 87% (92 of 106) to 97%

(103 of 106) (reader 1) and from 85% (90 of 106) to 96% (102 of 106) (reader 2) with parallel RF transmission (reader 1, P = .0078; reader 2, P = .002). Quality of parallel RF transmission images was assigned scores significantly higher, compared with quality of conventional Selleckchem Baf-A1 RF transmission images (mean for reader 1, 2.88 +/- 0.73 vs 4.04 +/- 0.44; mean for reader 2, 2.81 +/- 0.72 vs 4.04 +/- 0.39; P < .0001 for both). Lesion conspicuity scores were significantly higher on parallel RF transmission images, compared with conventional RF transmission images (mean for reader 1, 2.02 +/- 0.64 vs 2.92 +/- 0.27; mean for reader 2, 2.06 +/- 0.67 vs 2.90 +/- 0.30; P < .0001 for both). Contrast ratios were significantly higher with parallel RF transmission (P < .05).

Conclusion:

Compared with conventional RF transmission, parallel RF transmission significantly improved liver lesion detection rate, image quality, lesion conspicuity, and lesion contrast. (C) RSNA, 2011″
“Background: Depression is common among individuals with methamphetamine (MA) use disorders. As agents that enhance serotonergic function are frequently used to treat depression, one might predict that they would be useful medications for MA dependence. However, clinical trials of serotonergic agents for MA addiction find more have been unsuccessful.

Objective: To identify factors that distinguish MA-dependent research participants who increased MA self-administration while receiving treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline from other groups of participants.

Method: Using a dataset from a 12-week randomized, placebo-controlled trial of sertraline (100 mg daily) for MA addiction, we identified participants who had completed at least 8 weeks of the trial (n = 61 sertraline, n = 68 placebo). We compared the proportions of MA-positive urine tests for weeks 8-12 of the trial for these subjects to their pre-randomization baseline, and identified those subjects who increased MA use during treatment.